MARKET INTRODUCTION
Escitalopram is a drug used in the treatment of depression and generalized anxiety disorder. Escitalopram is an antidepressant belongs to as selective serotonin reuptake inhibitors group. These medicines increase activity of serotonin chemical inside the brain.
MARKET DYNAMICS
The escitalopram tablets market is driving due to the increasing prevalence of anxiety disorder and depression. Depression is the second-leading cause of disabilities globally. However, the introduction of generic variants on a large scale is expected to hamper the growth of the global Escitalopram Tablets market. Moreover, increasing demand for antidepressants due to minimum side effects and growing awareness levels amongst the consumers is anticipated to drive demand the growth of the market.
MARKET SCOPE
The "Escitalopram Tablets Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of escitalopram tablets market with detailed market segmentation by dosage, application, and distribution channel. The escitalopram tablets market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in escitalopram tablets market and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The escitalopram tablets market is segmented based on dosage, application, and distribution channel. Based on dosage, the market is segmented into 5 mg, 10 mg, and 20 mg. On the basis of application, the market is segmented into depression, obsessive-compulsive disorder, panic disorder, social anxiety disorder and generalized anxiety disorder. By distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and online.

REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the escitalopram tablets market based on various segments. It also provides market size and forecast estimates from year 2020 to 2028 with respect to five major regions, namely, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The escitalopram tablets market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting escitalopram tablets market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely, North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social, and technological factors effecting the escitalopram tablets market in these regions.

MARKET PLAYERS
The report covers key developments in the escitalopram tablets market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from escitalopram tablets market are anticipated to have lucrative growth opportunities in the future with the rising demand for escitalopram tablets market in the global market. Below mentioned is the list of few companies engaged in the escitalopram tablets market.
The report also includes the profiles of key players in Escitalopram Tablets market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- Forest Laboratories
- H. Lundbeck A/S
- Amneal Pharmaceuticals, LLC
- Aurobindo Pharma
- Macleods Pharma
- PharmaCare
- Jubilant Life Sciences Limited
- Lupin Pharmaceuticals, Inc.
- Teva Pharmaceutical Industries Ltd.
- Caraco Pharmaceutical Laboratories, Ltd.
The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.